Brickell Biotech gets temporary delisting reprieve from Nasdaq

BOULDER —  Brickell Biotech Inc. (Nasdaq: BBI) has received a 180-day extension to boost its stock price and retain Nasdaq compliance for listing on the exchange. 

According to a disclosure filed this week with the U.S. Securities and Exchange Commission, the clinical-stage pharmaceutical company that’s developing a gel to treat excessive sweating has until June 13, 2022, to demonstrate that the closing bid price of the firm’s common stock is at least $1 per share for a minimum of 10 consecutive business days.

If Brickell is unable to achieve this, Nasdaq is likely to delist the company, a move that Brickell can…